The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective phase II study of inoperable pancreatic adenocarcinoma with neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX).
Anthony Paul Gulati
No relevant relationships to disclose
Stephen M. Schreibman
No relevant relationships to disclose
Beth Schrope
No relevant relationships to disclose
James A. Lee
No relevant relationships to disclose
John Allendorf
No relevant relationships to disclose
John A. Chabot
No relevant relationships to disclose
Dawn Tsushima
No relevant relationships to disclose
Kelley B. Mowatt
No relevant relationships to disclose
Anna Oprescu
No relevant relationships to disclose
Kyung Chu
No relevant relationships to disclose
William H. Sherman
No relevant relationships to disclose
Ronald D. Ennis
No relevant relationships to disclose
Yoomi Lee
No relevant relationships to disclose
Robert Lance Fine
No relevant relationships to disclose